Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

An analysis by Li Tao, MD, MS, PhD, director of real-world evidence at Gilead Sciences, and colleagues looked at statistical ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...

“With low uptake of PrEP among the communities most impacted by HIV, this insurance coverage requirement with zero ...

In the last 30 years, HIV rates have gone down, in large part because of the game-changing prescription drug pre-exposure ...

Historically, as mentioned, PrEP has been used to treat cisgender gay men, especially in light of the HIV crisis of the 1980s ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Researchers from the HIV Prevention Trials Network (HPTN) presented results from HPTN 091 ("I Am Study") at the HIVR4P 2024 ...

Studies from OPERA and Trio cohorts provide further real-world evidence supporting CAB LA for PrEP’s high effectiveness and adherence in preventing HIV acquisition Patient-reported results for CAB LA ...